Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Chief Financial Officer | August 31, 2026 | September 02, 2026 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | July 01, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 10,000 |
Reported balance
After 2026-08-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-31 · Purchase · Acquired 10,000 · Balance 10,000 F1: The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 76,467 |
Reported balance
Holding disclosure · report date 2026-08-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 76,467 F3: Includes 2,039 shares previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") in a transaction that was exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
F3: Includes 2,039 shares previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") in a transaction that was exempt under Rule 16b-3(c).
X4 Pharmaceuticals, Inc
Report date July 01, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2036-07-01 | Direct | 110,000 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 110,000 · Balance 110,000 F1: The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 23:50 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 10,000 | $3.96 | $39,600.00 |
DisclosureSEC source: 0001628280-26-060234 · wk-form4_1788393010.xml · nonDerivative · entry 1 Gold Kelly · CIK 0002033333 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 10,000 F1 · price: The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 21:08 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 6,551 | $1.65 | $10,809.15 |
DisclosureSEC source: 0001628280-26-053511 · wk-form4_1785964091.xml · nonDerivative · entry 1 Gold Kelly · CIK 0002033333 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,428 F1 · price: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 20:20 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001501697-26-000064 · wk-form4_1782937206.xml · derivative · entry 1 Gold Kelly · CIK 0002033333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-07-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:47 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0002033333-26-000002 · wk-form4_1775249221.xml · derivative · entry 1 Gold Kelly · CIK 0002033333 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
| December 11, 2025 Filed Dec 22, 2025 22:41 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0002033333-25-000005 · wk-form4_1766443290.xml · derivative · entry 1 Gold Kelly · CIK 0002033333 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2035-12-10 F1 · derivative.exercise_date: This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:24 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 6,060 | $1.65 | $9,999.00 |
DisclosureSEC source: 0002033333-25-000003 · wk-form4_1757622271.xml · nonDerivative · entry 1 Gold Kelly · CIK 0002033333 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,877 F1 · price: On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:07 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001628280-25-016482 · wk-form4_1743710820.xml · derivative · entry 1 Gold Kelly · CIK 0002033333 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.